Abstract: The present invention provides the technique for isolating the toxin of the Sarcocystis protozoa, which may be later used in the production of specific antibodies against the sarcocystine responsible for the symptoms of sarcocystosis. The technique of the invention consists of separating the blood serum of an infected animal followed by dialysis thereof and finally the sample is dried. The technique is more effective when heart muscle material from an intermediate host with Sarcocystis cysts is used to contaminate a carnivorous mammal final host.
Abstract: Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, particularly in the anterior chamber of the eye. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
Abstract: A pharmaceutical formulation comprising a growth hormone and Leu-His-Leu as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
Type:
Grant
Filed:
January 13, 1995
Date of Patent:
January 6, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Thorkild Christensen, Per Balschmidt, Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim
Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 30, 1997
Assignee:
Cephalon, Inc.
Inventors:
Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
Abstract: A preventive for circulatory diseases which can prevent the onset of circulatory diseases, particularly cerebral stroke, without causing adverse effects such as blood-pressure fluctuation. The preventive contains as the active ingredient a low-molecular-weight peptide fraction prepared by the trypsinization of casein followed by partial purification.
Abstract: The invention relates to the use of hepatocyte and keratinocyte growth factors for stimulating the proliferation and motility of corneal cells in vivo and in vitro. Also disclosed is the use of these factors for maintaining the viability of corneal cells during or after ocular surgery and during corneal preservation in storage medium prior to transplant. Polymerase chain reaction amplification has demonstrated that corneal epithelial and endothelial cells in vitro and ex vivo corneal epithelium produce messenger RNA coding for hepatocyte growth factor, hepatocyte growth factor receptor, keratinocyte growth factor, and keratinocyte growth factor receptor. Several growth factors were found to inhibit the differentiation of corneal epithelial cells as measured by decreased expression of keratin K3. Methods for treating ocular dry eye diseases are presented.
Type:
Grant
Filed:
March 9, 1995
Date of Patent:
December 30, 1997
Assignee:
Board Of Regents, The University of Texas System
Abstract: A process is provided for producing a purified extract from Ginkgo biloba leaves by solvent extraction with selected solvents. In the process, a crude or partially purified extract is subjected to solvent extraction with a solvent comprising toluene and n-butanol. Pharmaceutical compositions comprising dimeric flavones and/or polyphenols are also described.
Type:
Grant
Filed:
March 12, 1996
Date of Patent:
December 23, 1997
Assignee:
Indena SpA
Inventors:
Ezio Bombardelli, Giuseppe Mustich, Marco Bertani
Abstract: A method of decreasing patient time in a catabolic state after a traumatic injury. The patient is administered systemically human growth hormone releasing factor or a biologically active analog of human growth hormone releasing factor. Administration in the case of voluntary traumatic injury such as surgery occurs just prior to commencing the surgery and thereafter continuing until recovery. In this way the time in a catabolic state is significantly decreased, and the patient moves more quickly to desired anabolic state necessary for recovery.
Type:
Grant
Filed:
March 24, 1995
Date of Patent:
December 23, 1997
Inventors:
Mark K. Gutniak, Thomas R. Coolidge, Robert R. Recker, Fred W. Wagner
Abstract: The present invention provides a polypeptide having an amino acid sequence represented by Sequence No. 1 and a cathepsin L-specific inhibitor and therapeutic agent for osteoporosis comprising the polypeptide as its effective component. Since the polypeptide possesses potent inhibitory action specific to cathepsin L as well as strong bone resorption inhibitory action, the polypeptide is useful in the treatment of osteoporosis, particularly, senile osteoporosis.
Abstract: The invention relates to neuropeptide Y-Y.sub.2 receptor specific peptides. Preferred peptides areas follows: ##STR1## The peptides are preferably used in relieving nasal congestion.
Type:
Grant
Filed:
October 28, 1994
Date of Patent:
December 9, 1997
Assignee:
CRC for Biopharmaceutical Research Pty Limited
Inventors:
Albert Tseng, Lisa Selbie, Erica Potter
Abstract: A method of treating primary and recurrent atheromatous plaque development is provided. The method involves administering a therapeutically effective amount of SERP-1, admixed in a pharmaceutically acceptable carrier to the intimal or lumenal layer of arterial walls. Biologically active SERP-1 analogs are also provided.
Abstract: A method of treating an ovarian estrogen dependent condition such as endometriosis, uterine leiomyomata, PMS or DUB involving the administration of gonadotropin releasing hormone analog and the administration of antiprogestin, which will provide a therapeutic method for long term treatment without rapid loss of bone density, as occurs using GnRH analogs alone.
Type:
Grant
Filed:
February 4, 1994
Date of Patent:
October 28, 1997
Assignee:
The Medical College of Hampton Roads
Inventors:
Gary D. Hodgen, Robert F. Williams, Daniel Grow
Abstract: A method of stabilizing bleomycin solutions and to the stable bleomycin solutions resulting therefrom are described. In the method described, bleomycin solution is stabilized by solubilizing bleomycin powder in an aqueous solution and storing the solution at reduced temperature while it awaits use.
Abstract: TGF.beta. is used to increase the numbers of stem cells in a subject's peripheral blood. Then the subject's blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF.beta. administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.
Abstract: Insulin-like growth factor (IGF) is used for treatment of type A insulin-resistant diabetes by reduction of glucose levels. The treatment is applicable to Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies.
Abstract: A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine hydroxylase by 2-amino-1,1,3-tricyano-1-propene are disclosed.
Type:
Grant
Filed:
October 12, 1995
Date of Patent:
September 9, 1997
Assignee:
East Carolina University
Inventors:
John Paul DaVanzo, Joseph West Paul, Jr.
Abstract: A regimen for the therapeutic management of a gonadal-steroid dependent condition in a mammal constitutes reducing the estrogen supply thereof by means of administration of a GnRH antagonist in an amount effective to inhibit proliferation of endometrial tissue without substantially stopping the production of endogenous estrogen. A method of determining whether the reduced estrogen supply in an individual is such that the concentration of estradiol has been suppressed to an optimized level appropriate to the therapeutic management of the gonadal-steroid dependent condition such as endometriosis in that individual by the administration of a GnRH antagonist at a given dosage level involves titering the dosage, e.g., by conducting a progesterone challenge test and optimal regimen doses of a GnRH antagonist.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 19, 1997
Assignees:
The Medical College of Hampton Roads, Ortho Pharmaceutical Corporation
Abstract: A method of lowering the pulmonary blood pressure of a subject suffering from pulmonary hypertension. The method includes administering to the subject an effective amount of a bombesin antagonist.